BLC
SUPN icon

Brown, Lisle/Cummings’s Supernus Pharmaceuticals SUPN Stock Holding History

Brown, Lisle/Cummings’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.4K Buy
+27
New +$1.38K ﹤0.01% 887

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brown, Lisle/Cummings's SUPN Position: Q1 2026 in Review

Brown, Lisle/Cummings opened a new position in Supernus Pharmaceuticals (SUPN) in Q1 2026: 27 shares worth $1.4K. The stake represents ﹤0.01% of the portfolio and ranks #887 among its holdings.

327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Brown, Lisle/Cummings held 27 shares of Supernus Pharmaceuticals worth $1.4K as of Q1 2026.
  • Supernus Pharmaceuticals was a new Brown, Lisle/Cummings position in Q1 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q1 2026, its #887 holding.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2026, filed 20 Apr 2026.